Skip to main content

ALS drug Relyvrio withdrawn from market after failed clinical trial

·1 min

Amylyx Pharmaceuticals has initiated the voluntary withdrawal of its ALS drug, Relyvrio, due to its lack of proven efficacy in a large clinical trial. The company stated that Relyvrio will no longer be available for new patients, but current patients can transition to a free drug program if they wish to continue the treatment. The Phase 3 clinical trial demonstrated that Relyvrio did not outperform a placebo in improving participants’ ALS functional scale, patient-reported quality of life, overall survival, and respiratory function. Amylyx will reduce its workforce and prioritize funding for ongoing studies of experimental drugs for other neurodegenerative disorders.